WAVE LIFE SCIENCES LTD. Deferred Revenue
WAVE LIFE SCIENCES LTD. (WVE) had Deferred Revenue of $1.27 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-05-09
- 2018-03-31: Deferred Revenue, Current $1.27M.
- 2017-12-31: Deferred Revenue, Current $1.27M; Deferred Revenue, Current as first filed $2.71M.
- 2017-09-30: Deferred Revenue, Current $2.71M.
- 2017-06-30: Deferred Revenue, Current $2.71M.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2018-03-31 | $1.27M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $1.27M 10-Q · filed 2018-05-09 | $2.71M 10-K · filed 2018-03-12 |
| 2017-09-30 | $2.71M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $2.71M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $2.71M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $2.71M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $2.71M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $2.50M 10-Q · filed 2016-08-15 | |
| 2014-12-31 | $152.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |